Sign in
Alex Fulton

Alex Fulton

Vice President and Equity Research Analyst at Truist

Atlanta, GA, US

Alex Fulton is a Vice President and Equity Research Analyst at Truist, focusing on financial institutions with a specialization in banking and financial services companies. He covers major regional and national banks, leveraging in-depth sector analysis to support investment decisions, although specific performance metrics and rankings are not publicly available. Alex began his career in the financial industry prior to joining Truist and has advanced to his current role as Vice President, demonstrating expertise developed over several years in equity research. He holds industry-standard professional credentials including FINRA securities licenses, reflecting his regulatory compliance and standing as a registered representative.

Alex Fulton's questions to NEUROCRINE BIOSCIENCES (NBIX) leadership

Question · Q3 2025

Alex Fulton inquired about any new shifts in CRENESSITY's new prescription breakdown between pediatrics and adults, and trends in the usage of the free drug program.

Answer

Eric Benevich, Chief Commercial Officer, reported no major demographic shifts, with prescriptions still skewing towards younger and primarily female patients, a pattern consistent since about a quarter post-launch. He noted that usage of the free drug program continues to be less than anticipated, as 9 out of 10 patients receive insurance approval, minimizing the need for the program.

Ask follow-up questions

Fintool

Fintool can predict NEUROCRINE BIOSCIENCES logo NBIX's earnings beat/miss a week before the call

Question · Q3 2025

Alex Fulton asked about CRENESSITY, inquiring if there were any new shifts in the new prescription breakdown between pediatrics and adults, and trends in the usage of the free drug program.

Answer

Eric Benevich, Chief Commercial Officer, reported no major demographic shifts, with prescriptions still skewing towards younger and primarily female patients, a pattern consistent since about a quarter into launch. He also noted that usage of the free drug program continues to be less than anticipated, as 9 out of 10 patients receive insurance approval.

Ask follow-up questions

Fintool

Fintool can write a report on NEUROCRINE BIOSCIENCES logo NBIX's next earnings in your company's style and formatting

Let Fintool AI Agent track Alex Fulton for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%

Try Fintool for free